Thanks to the generosity of our sponsors, we are now offering complimentary registration! In lieu of a registration fee, we ask that you kindly consider donating to help fund cancer-related and COVID-19-related charitable organizations so that we may exceed the more than $20,000 we donated in 2020. Click the button below to donate. Thank you for your generosity and support!

We believe that tumor agnostic approval will replace the traditional tumor and stage specific path. The FDA approval pembrolizumab for MSI tumors, and both Larotrectinib and Entrectinib for NTRK fusions has set the path. Richard Pazdur, MD, Acting Director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research and Director of the FDA’s Oncology Center of Excellence quotes re the pembrolizumab approval: “The review of pembrolizumab for this indication was based on overall response rate and durability of response. Of the 149 patients who received pembrolizumab in these studies, 39.6% had a complete or partial response. For 78% of those patients, the response lasted 6 months or longer.” To further quote Dr Pazdur: “This new indication represents a shift in our evaluation of therapies. The approval moves us away from the strict disease-site indication, such as breast, colon, or lung cancer, to a site-agnostic indication. It changes how we may define cancer—the disease is no longer being solely determined by its site of origin or pathologic diagnosis. It is now defined by the presence of a specific biomarker.” This will lead to much smaller trial sizes and accelerated drug development and approval. Moderator Julie R. Gralow, MD, FACP, FASCO, EVP & CMO, American Society of Clinical Oncology Association for Clinical Oncology.